United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,794 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,794 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $355.54, for a total transaction of $2,771,078.76. Following the completion of the transaction, the chief financial officer now owns 5,344 shares in the company, valued at $1,900,005.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $358.62, for a total transaction of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The shares were sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Stock Up 1.7 %

United Therapeutics stock opened at $355.79 on Wednesday. The company has a market cap of $15.78 billion, a P/E ratio of 16.82, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The company has a fifty day simple moving average of $344.71 and a 200 day simple moving average of $301.85. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the business posted $5.24 EPS. Research analysts anticipate that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after acquiring an additional 4,100 shares during the period. Comerica Bank grew its position in shares of United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after acquiring an additional 9,244 shares during the period. Tri Locum Partners LP bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $15,959,000. Finally, QRG Capital Management Inc. grew its position in shares of United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after acquiring an additional 1,692 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. TD Cowen increased their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. Bank of America cut their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $357.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.